The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs

CMAJ. Canadian Medical Association Journal

Volumn 165, Issue 7, 2001, Pages 917-928

  Kalant, H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYPHENYL N METHYLBUTANAMINE; 4 METHOXYAMPHETAMINE; ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE DERIVATIVE; EPHEDRINE; MESCALINE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; UNCLASSIFIED DRUG;

ACCIDENT; CEREBROVASCULAR ACCIDENT; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MECHANISM; DRUG SAFETY; ENDURANCE; ENERGY; HEART ARRHYTHMIA; HUMAN; HYPERPYREXIA; LIVER NECROSIS; MENTAL DISEASE; NEUROTOXICITY; REVIEW; RHABDOMYOLYSIS; SEROTONINERGIC SYSTEM; SEXUAL AROUSAL; SOCIAL ADAPTATION; SUICIDE;

EID: 0035664224     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (191)

1. Ecstacy [sic]: A review of MDMA and MDA
2. The background and chemistry of MDMA
3. Mescaline analogs ("designer drugs")
4. Tissue distribution of methylenedioxymethamphetamine
5. Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning
6. Grand-mal-serie nach ecstasy-einnahme
7. Deaths associated with MBDB use
8. Pathology of deaths associated with "ecstasy" and "eve" misuse
9. Nouvelles drogues synthétiques empathogènes
10. Screening experiments of ecstasy street samples using near infrared spectroscopy
11. "Ecstasy"
12. Analysis of illicit ecstasy tablets: Implications for clinical management in the accident and emergency department
13. Amphetamine designer drugs - An overview and epidemiology
14. MDMA - Nonmedical use and intoxication
15. Ecstasy (MDMA) effects upon mood and cognition before, during, and after a Saturday night dance
16. MDMA induced hyperthermia: Report of a fatality and review of current therapy
17. Fatal multi-organ failure after suicidal overdose with MDMA, 'ecstasy': Case report and review of the literature
18. Lethal monointoxication by overdosage of MDEA
19. 'Ecstasy' and intracerebral haemorrhage
20. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans
21. The complications of 'ecstasy' (MDMA)
22. Interactions of amphetamine analogs with human liver CYP2D6
23. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('ecstasy')
24. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
25. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy")
26. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners
27. Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices
28. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") are attenuated by the serotonin uptake inhibitor citalopram
29. MDMA stimulus generalization to the 5-HT(1A) serotonin agonist 8-hydroxy-2-(di-n-propylamino)tetralin
30. Acute psychological and physiological effects of MDMA ("ecstasy") after haloperidol pretreatment in healthy humans
31. The action of some amines related to adrenaline: Methoxy-phenylisopropylamines
32. MDMA ('ecstasy') enhances basal acetylcholine release in brain slices of the rat striatum
33. MDMA as a discriminative stimulus: Isomeric comparisons
34. Initial characterization of PMMA as a discriminative stimulus
35. Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination
36. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat
37. Stereochemistry of the metabolism of MDMA to MDA
38. Subjective reports on the effects of the MDMA ('ecstasy') experience in humans
39. Die entaktogene "ecstasy" (MDMA), "eve" (MDEA) und andere ringsubstituirte methamphetaminderivate. Eine neue stoffklasse unter den illegalen designerdrogen?
40. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users
41. Differences between the mechanisms of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: Entactogens
42. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers
43. Subjective reports of the effects of MDMA in a clinical setting
44. MDMA ("ecstasy") - Gefährliche droge oder psychotherapeutikum?
45. LSD revisited. A 10-year follow-up of medical LSD use
46. Ecstasy and the dance of death
47. Environmental and drug-induced hyperthermia. Pathophysiology, recognition and management
48. 3,4-Methylenedioxymethamphetamine (MDMA) and other substituted amphetamines
49. Toxicity of drug abuse - Amphetamine designer drugs (ecstasy): Mental effects and consequences of single dose use
50. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('ecstasy')
51. MDMA (ecstasy) precipitation of panic disorder
52. Potential human neurotoxicity of MDMA ('ecstasy'): Subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies
53. MDMA ("ecstasy") - Konsum - Ein überblick zu psychiatrischen und medizinischen folgen
54. Three cases of delirium after "ecstasy" ingestion
55. "Saturday night fever": Ecstasy related problems in a London accident and emergency department
56. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy")
57. Cocaine and other stimulants. Actions, abese, and treatment
58. MDMA (ecstasy) neurotoxicity: Assessing and communicating the risks
59. The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long-term degeneration of 5-HT neurons in brain: A comparison with MDMA ("ecstasy")
60. 3,4-Methylenedioxy analogues of amphetamine: Defining the risks in humans
61. (+/-)3,4-Methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: Studies in animals
62. Free radicals and the pathobiology of brain dopamine systems
63. Striatal serotonin is depleted in brain of a human MDMA (ecstasy) user
64. (+/-)3,4-Methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: Clinical studies
65. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"): A controlled study in humans
66. Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings
67. Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy')
68. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users
69. Cerebral (1)H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users
70. Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: A co-registered SPECT and MRI ctudy
71. Ecstasy - Long-term effects on the human central nervous system revealed by positron emission tomography
72. MDMA ("ecstasy") and its association with cerebrovascular accidents: Preliminary findings
73. Memory disturbances in "ecstasy" users are correlated with an altered brain serotonin neurotransmission
74. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in humans correlates with EEG power and coherence
75. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users
76. Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecctasy) on serotonin system function in humans
77. Serotonergic function after (+/-)3,4-methylenedioxymetamphetamine ('ecstasy') in humans
78. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users
79. Is MDMA ('ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research
80. Memory impairment in abstinent MDMA ("ecstasy") users
81. Memory deficits associated with recreational use of "ecstasy" (MDMA)
82. Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: Cognitive and behavioural indices of change
83. A pure amnestic syndrome after MDMA ("ecstasy") ingestion
84. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
85. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
86. Working memory deficits in current and previous users of MDMA ('ecstasy')
87. Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity
88. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users
89. Trastorno psicótico persistente inducido por consumo de extasis (MDMA)
90. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "ecstasy")
91. 'Ecstasy' psychosis and flashbacks
92. Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users
93. M.D.M.A. ("ecstasy"); a case of possible drug-induced psychosis
94. "Ecstasy"-induziertes psychotisches depersonalisations-syndrom
95. Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy")
96. Long term psychiatric and cognitive effects of MDMA use
97. The occurrence of toothwear in users of ecstasy (3,4-methylenedioxymethamphetamine)
98. An association between the regular use of 3,4-methylenedioxymethamphetamine ("ecstasy") and excessive wear of teeth
99. Cardiovascular autonomic dysregulation in users of MDMA ("ecstasy")
100. Parkinsonism after taking ecstasy
101. Bilateral sixth nerve palsy associated with MDMA ("ecstasy") abuse
102. Ecstasy: A common cause of severe acute hepatotoxicity
103. Mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications
104. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: Effect on cytosolic calcium signals in isolated hepatocytes
105. Metabolism of methylenedioxymethamphetamine: Formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct
106. Acuut leverfalen door methylenedioxymethamphetamine
107. Ecstasy induced hepatitis mimicking viral hepatitis
108. Chronic ecstasy (3,4-methylenedioxymethamphetamine) abuse: A recurrent and unpredictable cause of severe acute hepatitis
109. Misuse of ecstasy
110. Hepatitis aguda tras consumo de extacis
111. Misuse of ecstasy
112. Acute liver damage and ecstasy ingestion
113. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")
114. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymethamphetamine ("ecstasy") usage
115. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy
116. Auxiliary liver transplantation: Regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure - A multicenter European study
117. Auxiliäre lebertransplantation bei akuten leberversagen nach einnahme von 3,4-Methylendioxymetamphetamin ("ecstasy")
118. Subarachnoidal haemorrhage associated with MDMA abuse
119. Intracranial haemorrhage associated with ingestion of 'ecstasy'
120. Hemorragie cérébrale et "ecstasy"
121. Retinal haemorrhage caused by "ecstasy"
122. Cerebral infarction in association with ecstasy abuse
123. Epileptische insulten, herseninfarct en rhabdomyolysis als complicaties van amfetamingebruik
124. Cerebral venous sinus thrombosis induced by 'ecstasy'
125. "Ecstasy" and sudden cardiac death
126. Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion
127. Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA)
128. Hyponatraemia and seizures after ecstasy use
129. Cerebral oedema after MDMA ("ecstasy") and unrestricted water intake: Hyponatraemia must be treated with low water input
130. Hyponatraemia after ingestion of "ecstasy"
131. Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female
132. Cerebral oedema after ingestion of MDMA ("ecstasy") and unrestricted intake of water
133. Hyponatraemia and catatonic stupor after taking ecstasy
134. Death from hyponatraemia-induced cerebral oedema associated with MDMA ("ecstasy") use
135. Hyponatraemia and death after "ecstasy" ingestion
136. Accidental ingestion of 'ecstasy' (3,4-methylenedioxymethylamphetamine)
137. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat
138. Multiple severe complications from recreational ingestion of MDMA ('ecstasy')
139. Amphetamine intoxication with coagulopathy, hyperthermia and reversible renal failure. A syndrome resembling heatstroke
140. Rhabdomyolysis and shock after intravenous amphetamine administration
141. Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('eve')
142. Ecstasy intoxication: An overlap between serotonin syndrome and neuroleptic malignant syndrome
143. Drug-induced hyperthermia
144. Muscle changes in the neuroleptic malignant syndrome
145. Bilateral gluteal compartment syndrome after 'ecstasy' hyperpyrexia
146. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse
147. Acute renal failure after ecstasy
148. Ecstasy, 3,4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia
149. Methylenedioxyamphetamine. Clinical description of overdose, death, and review of pharmacology
150. The agony of "ecstasy"
151. Dantrolene and "ecstasy"
152. An overdose of ecstasy. A role for dantrolene
153. Survival following 'ecstasy' ingestion with a peak temperature of 42°C
154. Ecstasy intoxication: Appreciation of complications and the role of dantrolene
155. An unusual case of ecstasy poisoning
156. Exertional heat stroke induced by amphetamine analogues: Does dantrolene have a place?
157. Immunomodulating properties of MDMA alone and in combination with alcohol: A pilot study
158. Two very different fatal cases associated with the use of methylenedioxyethylamphetamine (MDEA): Eve as deadly as Adam
159. Intentional overdose and death with 3,4-methylenedioxyethamphetamine (MDEA; "eve"): Case report
160. 'Eve' and 'ecstasy' - A report of five deaths associated with the use of MDEA and MDMA
161. Reckless behaviour related to the use of 3,4-methylenedioxymethamphetamine (ecstasy): Apropos of a fatal accident during car-surfing
162. Amphetamine derivative related deaths
163. Death in amphetamine users: Causes and rates
164. PMA deaths in Ontario
165. Recent paramethoxyamphetamine deaths
166. Amphetamine derivative fatalities in South Australia - Is "ecstasy" the culprit?
167. Hyperpyrexia associated with fatal paramethoxyamphetamine abuse
168. Another death from ecstasy
169. 3,4-Methylenedioxyamphetamine: Analytical and forensic aspects of fatal poisoning
170. A fatal trip with ecstasy: A case of 3,4-methylenedioxymethamphetamine/3,4-methylenedioxyamphetamine toxicity
171. 'Adam' or 'Eve'? - A toxicological conundrum
172. Traffic fatality related to the use of methylenedioxymethamphetamine
173. Adam (MDMA) and Eve (MDEA) misuse: An immunohistochemical study on three fatal cases
174. Fatal poisoning by MDMA (ecstasy) and MDEA: A case report
175. A fatal overdose with 3,4-methylenedioxyamphetamine derivatives
176. Fatal interaction between ritonavir and MDMA
177. 3,4-Methylenedioxyamphetamine overdose
178. Death by "ecstasy": The serotonin syndrome?
179. Fatal intoxication from 3,4-methylenedioxyamphetamine
180. A fatal case involving methylenedioxyamphetamine
181. Death after ecstasy ingestion: Neuropathological findings
182. Ecstasy (MDMA) dependence
183. Musical preference as an indicator of adolescent drug use
184. Ecstasy and new patterns of drug use: A normal population study
185. MDMA ('ecstasy') consumption in the context of polydrug abuse: A report on 150 patients
186. Notfälle bei drogenmissbrauch
187. Fatal uncertainty: Death rate from use of ecstasy or heroin